# Gavin Bell

> Gavin Bell is a seed investor at Maven Capital Partners backing Health Care and Biotechnology. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Maven Capital Partners](https://shizune.co/investors/profile/maven-capital-partners)
- Location: Manchester, United Kingdom
- Total investments: 12
- Last investment: Jun 2024
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/gavin-bell-cfa-4443a29/

Gavin Bell is a seed investor at Maven Capital Partners in Manchester focused on Health Care and Biotechnology. Gavin joined Maven in September 2016 as an Investment Manager based in the Manchester office, responsible for new investments across Greater Manchester and the North of England. Gavin has over 10 years of experience in Private Equity. Prior to joining Maven, he was at NorthEdge Capital in Manchester where he was responsible for both new privateequity investment activity and fundraising. Gavin began his private equity career at Greenpark Capital (now Stepstone), a secondaries private equity fund manager in London investing into private equity funds globally, where he spent 8 years. His prior experience was as an analyst at Schroders in London, where he spent 5 years, and at Bank of New York.Gavin holds a Bsc. (Hons) in Economics from the University of Birmingham and is a CFA Charterholder.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 33% |
| Biotechnology | 3 | 25% |
| Life Science | 2 | 17% |
| Fitness | 1 | 8% |
| Medical | 1 | 8% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 4 | 33% |
| Funding Round | 4 | 33% |
| Venture - Series Unknown | 3 | 25% |
| Series A | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Alderley Lighthouse Labs | Alderley Lighthouse Labs is a laboratory-based testing facility, specializing in human diagnostics. |  | Venture - Series Unknown | Jun 27, 2024 |  |
| Alderley Lighthouse Labs | Alderley Lighthouse Labs is a laboratory-based testing facility, specializing in human diagnostics. | $1.3M |  | Aug 14, 2023 |  |
| Alderley Lighthouse Labs | Alderley Lighthouse Labs is a laboratory-based testing facility, specializing in human diagnostics. | $1.3M | Seed | Aug 14, 2023 |  |
| Biorelate | Biorelate provides biomedical research services. It engages in the research of biomarkers for the diagnosis of prostate cancer; target validation; and new drug development services. Daniel Jamison founded Biorelate in 2014. It has its headquarters in Oldham in the United Kingdom. | $7.8M | Series A | Nov 29, 2022 |  |
| Cryoniss | Cryoniss is a life sciences company. They provide a range of temperature-controlled biological sample storage and logistics services, as well as access to samples, to organizations conducting scientific research. | $682.4K | Seed | Jan 17, 2022 |  |
| XR Games | XR Games (based in Leeds, England) makes both console and mobile Virtual and Augmented Reality (VR/AR) games for world famous Intellectual Properties. XR Games is an innovative start-up with Venture Capital funding. | $2M |  | Aug 16, 2021 |  |
| XR Games | XR Games (based in Leeds, England) makes both console and mobile Virtual and Augmented Reality (VR/AR) games for world famous Intellectual Properties. XR Games is an innovative start-up with Venture Capital funding. | $2.1M | Seed | Aug 16, 2021 |  |
| Blueberry Therapeutics | Blueberry Therapeutics Ltd. is a modern drug discovery and development company which puts people first whether patients, employees, investors or partners. We have created an open, imaginative and fun team environment with a very serious objective: to create new, safer and more effective medicines to treat human disease and make patients feelbetter. Blueberry focuses on the research and development of treatments for inflammatory and infectious diseases. We do this by employing state of the art preclinical research technologies to generate potent selective and safe molecules (peptides, antibodies, small molecules) for clinical development into new effective treatments to benefit patients. By focusing on well validated drug targets and ensuring our candidate molecules have a very low toxicity liability we believe we can mitigate or even avoid two of the major reasons for drug failures in the clinic. | $1.1M | Venture - Series Unknown | Jun 08, 2021 |  |
| Healum | Healum provides connected software and apps to improve self-management for patients with long term conditions. Healum enables people to cost effectively monitor and understand their physical and mental health. |  | Venture - Series Unknown | Mar 25, 2021 |  |
| Flynotes | Flynotes is an innovative digital consent platform, improving patient safety across healthcare. |  |  | Nov 24, 2020 |  |

10 of 12 investments shown.

## Co-investors
- [Act Media Ventures](https://shizune.co/investors/profile/act-capital-partners) — VC Fund, 2 deals together
- [GM&C Life Sciences Fund](https://shizune.co/investors/profile/gm-c-life-sciences-fund) — VC Fund, 2 deals together
- [Praetura Ventures](https://shizune.co/investors/profile/praetura-capital) — VC Fund, 2 deals together
- [Seneca Partners](https://shizune.co/investors/profile/seneca-partners-aa41) — VC Fund, 2 deals together
- [Manchester Tech Trust Angels](https://shizune.co/investors/profile/manchester-tech-trust-angels) — VC Fund, 1 deal together
- [Northern Powerhouse Investment Fund](https://shizune.co/investors/profile/northern-powerhouse-investment-fund) — VC Fund, 1 deal together

## About Maven Capital Partners

VC Fund · Glasgow, United Kingdom

Maven Capital Partners was formed in 2009 following a management buyout of the private equity business of Aberdeen Asset Management PLC. Maven is now one of the UK’s leading private equity firms in the lower-mid market, specialising in investments in high-growth British companies. With a focus on innovation and value creation, Maven partners withvisionary entrepreneurs to build market-leading businesses, supporting a range of transaction types, including management buyouts, growth capital, buy-and-build projects, equity value release, and pre-IPO financing.Since 2009, Maven has also helped institutional, private client, and retail investors access private markets, including tax-efficient Venture Capital Trusts, deal-by-deal co-investment in private equity and property, and institutional buyout funds.

5 contacts available at Maven Capital Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Andy Round | Investment Director | https://shizune.co/investors/profile/andy-round-6fc8 |
| Dave Furlong | Investment Director | https://shizune.co/investors/profile/dave-furlong |
| Gavin Bell | Investment Manager | https://shizune.co/investors/profile/gavin-bell |
| James Darlington | Investment Manager | https://shizune.co/investors/profile/james-darlington |
| Jock Gardiner | Partner | https://shizune.co/investors/profile/jock-gardiner |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Gavin Bell invest in?

Gavin Bell invests primarily in Health Care, Biotechnology and Life Science startups, most often at Seed and Funding Round stage. Most of the 12 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Gavin Bell last invest?

The most recent investment recorded for Gavin Bell closed in Jun 2024. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co